Showcasing Tubulin Inhibitor Payload Innovation to Develop Novel ADCs & Subvert Patient Resistance to Established Mechanisms
- Weighing up novel payload development through evolving existing payload classes versus pursuing novel mechanisms
- Leveraging new and advanced tools to investigate novel tubulin payload development
- Contextualising payload innovation through ADC programmes and understanding significance for nextgeneration ADC development